Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds

Advertising today archive

3121 PWToday Stories

Make no bones

21 Jan 09

Heal Thyself

09 Jan 09

Truvada: Gilead vs Teva

17 Dec 08

PharmiWeb TodayGilead Sciences has filed a patent infringement lawsuit in New York against Teva Pharmaceuticals and Teva Pharmaceutical Industries Ltd relating to emtricitabine, a component of Truvada(R) (emtricitabine and tenofovir disoproxil fumarate).

Truvada is currently protected by 10 patents, which are listed in the FDA's Approved Drugs Products List, and all 10 patents would need to be invalidated or expired before a generic version of Truvada could be marketed. Gilead has full confidence in the strength of its patent position and plans to vigorously defend the intellectual property rights of Truvada.

Truvada is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.